In RCC, the reduction of PD-L1 expression with CPS treatment could allow for a better anti-tumor immune response, so CPS or TRPV1 agonists could be suggested as immuno-adjuvants in the RCC therapy. This evidence concerns the gene TRPV1 and renal cell carcinoma.